Evidence map›Paper›PMID 23508638›Full record

ArticleCarcinogenesis2013

Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck.

Lei Jin, Erich M Sturgis, Yang Zhang, Zhigang Huang, Peng Wei, Wei Guo, Zhongqiu Wang, Qingyi Wei, Xicheng Song, Guojun Li

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. MDM2 SNP309 is an ethnicity-dependent risk factor for digestive tract cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  4. Genomic alterations in oral multiple primary cancers.International journal of oral science · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Lei JinDepartment of Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Erich M Sturgis
Yang Zhang
Zhigang Huang
Peng Wei
Wei Guo
Zhongqiu Wang
Qingyi Wei
Xicheng Song
Guojun Li
The University of Texas MD Anderson Cancer Center · USCapital Medical University · CNShanghai East Hospital · CNSouthern Medical University · CNThe University of Texas Health Science Center at Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Molecular Epidemiology of Head and Neck CancerR01ES011740 · NIEHS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WEI, QINGYI · 2001 to 2012
$6.3M
Predictors of HPV16 Status and Outcomes of Oropharyngeal Cancer PatientsK07CA133099 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, GUOJUN · 2008 to 2012
$680k
Cytokine Variants as Predictors of HPV-16 Status & Outcome of Oropharyngeal CanceR03CA135679 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, GUOJUN · 2008 to 2009
$154k
NCI NIH HHS CA133099NCI NIH HHS CA135679NCI NIH HHS K07 CA133099NCI NIH HHS P30 CA016672NCI NIH HHS P-30 CA-16672NCI NIH HHS R03 CA135679NIEHS NIH HHS R01 ES011740NIEHS NIH HHS R01 ES-11740
6 · The paper itself

Abstract

Because of their important roles in mediating the stabilization and expression of p53, we hypothesized that high-risk genotypes of polymorphisms in p53-related genes, including p53, p73, p14(ARF), MDM2 and MDM4, may be associated with an increased risk of second primary malignancy (SPM) after index squamous cell carcinoma of the head and neck (SCCHN). We analyzed data from a cohort of 1283 patients with index SCCHN who were recruited between 1995 and 2007 at MD Anderson Cancer Center and followed for SPM development. Patients were genotyped for nine polymorphisms of p53-related genes. A log-rank test and Cox models were used to compare SPM-free survival and risk. Our results demonstrated that each p53-related polymorphism had a moderate effect on increased SPM risk, but when we combined risk genotypes of these nine polymorphisms together, we found that SPM-free survival was significantly shorter among risk groups with a greater number of combined risk genotypes. SPM risk increased with increasing number of risk genotypes (P < 0.0001 for trend). Compared with the low-risk group (0-3 combined risk genotypes), both the medium-risk (4-5 combined risk genotypes) and high-risk (6-9 combined risk genotypes) groups had significantly increased SPM risk [hazard ratio (HR): 1.6; 95% confidence interval (CI): 1.0-2.6 and HR: 3.0; 95% CI: 1.8-5.0, respectively]. Moreover, such significant associations were even higher in several subgroups. Our findings suggest that combined risk genotypes of p53-related genes may jointly modify SPM risk, especially in patients who are smokers and those with index non-oropharyngeal cancers. However, larger studies are needed to validate our findings.

Indexed as

Genes, p53Genetic Predisposition to DiseasePolymorphism, GeneticBiomarkers, TumorCarcinoma, Squamous CellCell Cycle ProteinsCohort StudiesConfidence IntervalsDNA-Binding ProteinsFemaleFollow-Up StudiesGenetic Association StudiesGenotypeHead and Neck NeoplasmsHumansMaleBiomarkers, TumorCell Cycle ProteinsDNA-Binding ProteinsMDM2 protein, humanMDM4 protein, humanNuclear ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2TP73 protein, humanTumor Protein p73Tumor Suppressor Protein p14ARFTumor Suppressor Proteins

Identifiers

PMID23508638
PMCPMC3697893
OpenAlexW2098169206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.